Videos

From Clinical Trials to Clinic: Making Sense of Rheumatology Metrics, with Roy Fleischmann, MD

ByRoy M. Fleischmann, MD

February 23rd 2026

Flesichmann shared highlights from his talk at RWCS 2026.

Precision Medicine and the Pursuit of Remission in RA and PsA, with Arthur Kavanaugh, MD

ByArthur Kavanaugh, MD

February 20th 2026

Kavanaugh discussed how far the field is to true precision medicine at RWCS 2026.

Advancing Research and Access in Modern Osteoporosis Care, with Gina Woods, MD

ByGina Woods, MD

February 19th 2026

Woods discussed integrating exercise into osteoporosis care and high priority research questions.

GLP-1 RAs and Beyond: Integrating Metabolic Health into PsA and RA Care, with Eric Ruderman, MD

GLP-1s and Beyond: Integrating Metabolic Health into PsA and RA Care, with Eric Ruderman, MD

ByEric M. Ruderman, MD

February 18th 2026

Ruderman emphasized growing interest in metabolic health with the rise of GLP-1 RA usage.

What Mattered Most in 2025 for RA and PsA, with Arthur Kavanaugh, MD

ByArthur Kavanaugh, MD

February 17th 2026

Kavanaugh discussed priorities in the disease fields in the last year of research.

Optimizing Osteoporosis Prevention and Therapy Selection, with Gina Woods, MD

ByGina Woods, MD

February 14th 2026

Woods discussed navigating conversations with patients about preventive therapy and the benefit-risk profile.

Do Updated Vasculitis Classification Criteria Change Practice, With Anisha Dua, MD

ByAnisha B. Dua, MD, MPH

February 14th 2026

Dua discussed the latest guideline updates, the most recent since 1990.

Treatment Choices and Sequencing in PsA, With Eric Ruderman, MD

ByEric M. Ruderman, MD

February 13th 2026

Ruderman discussed recent research examining treatment choices after failure.

Integrating Muscle, Nutrition, and Function into Bone Care, with Gina Woods, MD

ByGina Woods, MD

February 13th 2026

Woods shared extra-rheumatological considerations to keep in mind when managing patients' bone health.

Improving Diagnostic Precision and Long-Term Control in Large Vessel Vasculitis, with Anisha Dua, MD, MPH

ByAnisha B. Dua, MD, MPH

February 12th 2026

Dua emphasized exciting progress in the field for giant cell and arteritis and Takeyasu arteritis.

Difficult-to-Treat Disease in PsA and axSpA: Lessons from 2025, with Eric Ruderman, MD

ByEric M. Ruderman, MD

February 11th 2026

Ruderman discussed the topics of his year in review talks at RWCS 2026.

Breakthrough Therapy Ianalumab Efficacious, Safe for Sjögren, With Thomas Grader-Beck, MD

ByThomas Grader-Beck, MD

February 4th 2026

Grader-Beck emphasized the potential of ianalumab for improving treatment options for Sjögren disease.

Arthritis Still Limits Work and Daily Life for Millions, With Daniel White, MS, ScD

ByDaniel K. White, MS, ScD

February 3rd 2026

Rheumatoid Arthritis Awareness Day: Gaps Remain Despite Therapeutic Advances

ByVictoria Johnson

February 2nd 2026

Arthur Mandelin, MD, PhD, and Daniel White, MS, ScD, share what they consider the largest current unmet need in the RA field.

SC Anifrolumab and Other Advances in Lupus, with Susan Manzi, MD, MPH

BySusan Manzi, MD, MPH

January 29th 2026

Manzi reflected on progress in the lupus field and more research to be done with anifrolumab and beyond.

Breakthrough Therapy Ianalumab Nears FDA Submission for Sjögren, With Thomas Grader-Beck, MD

ByThomas Grader-Beck, MD

January 28th 2026

Subcutaneous Anifrolumab and Aiming for Remission in SLE, with Susan Manzi, MD, MPH

BySusan Manzi, MD, MPH

January 27th 2026

Manzi discussed shifting goals to remission in the lupus field.

Subcutaneous Anifrolumab Expands Treatment Flexibility for SLE, With Susan Manzi, MD, MPH

BySusan Manzi, MD, MPH

January 23rd 2026

Manzi discussed findings from the phase 3 TULIP-SC trial of subcutaneous anifrolumab for systemic lupus erythematosus.

Deucravacitinib, Zasocitinib Validate TYK2 Inhibition in PsA, With Philip Mease, MD

ByPhilip J. Mease, MD

January 21st 2026

Mease discussed the latest updates on deucravacitinib and zasocitinib at ACR Convergence 2025.

The Expanding Lupus Pipeline: Obinutuzumab and What's Next, With Rosalind Ramsey-Goldman, MD

ByRosalind Ramsey-Goldman, MD

January 13th 2026

Ramsey-Goldman discussed how the lupus field has shifted from her earlier career.

Nerandomilast Approval Expands Treatment Options for PPF, With Shervin Assassi, MD

December 23rd 2025

Assassi reflects on the FDA approval of nerandomilast for progressive pulmonary fibrosis and the clinical benefits of the new PDE4B-targeted treatment option.

Polygenic Risk Scores Linked to Specific SLE Manifestations, With Matthew Dapas, PhD

ByMatthew Dapas, PhD

December 4th 2025

ACR 2025 research shows polygenic risk scores correlate with specific SLE phenotypes, highlighting potential applications for clinical risk assessment.

Matthew Dapas, PhD I Credit: Feinberg School of Medicine

Polygenic Risk Scores Reveal Genetic Drivers of Lupus Heterogeneity, With Matthew Dapas, PhD

ByMatthew Dapas, PhD

November 24th 2025

At ACR 2025, Dapas discusses how polygenic risk scores link genetic risk to SLICC criteria, advancing precision medicine in systemic lupus erythematosus.